Literature DB >> 32301920

Reduced Antibiotic Exposure by Serial Physical Examinations in Term Neonates at Risk of Early-onset Sepsis.

Anlaug Vatne1,2, Claus Klingenberg3,4, Knut Øymar1,2, Arild E Rønnestad5,6, Paolo Manzoni7, Siren Rettedal1.   

Abstract

BACKGROUND: Suspected early-onset sepsis (EOS) results in antibiotic treatment of a substantial number of neonates who are uninfected. We evaluated if an approach using serial physical examinations (SPEs) can reduce antibiotic exposure for suspected EOS in term neonates during the first 3 days of life, without affecting safety.
METHODS: Within a quality-improvement framework, SPEs for 24-48 hours for neonates with suspected EOS was implemented in the neonatal intensive care unit, Stavanger, Norway. The proportion of neonates ≥37 weeks gestation exposed to antibiotics, antibiotic therapy-days and the safety outcome time from birth to start antibiotics were compared between a baseline period (April 2014-February 2016), when a risk factor based approach was used, and a post-SPE-implementation period (January 2017-November 2018).
RESULTS: We included all term live born neonates (n = 17,242) in the 2 periods. There was a 57% relative reduction in neonates exposed to antibiotics; 2.9% in the baseline and 1.3% in the post-implementation period, P < 0.001. There was a 60% relative reduction in mean antibiotic therapy-days/1000 patient-days; from 320 to 129, P < 0.001, and a 50% relative reduction in time to initiate antibiotics in suspected EOS-cases, from median (interquartile range) 14 (5-28) to 7 (3-17) hours, P = 0.003. The incidence of culture-positive EOS remained unchanged. There were no infection-attributable deaths.
CONCLUSIONS: Implementing SPE to guide empiric antibiotic therapy in term neonates with suspected EOS more than halved the burden of antibiotic exposure, without delay of antibiotic treatment of infected neonates or increased sepsis-related mortality.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32301920     DOI: 10.1097/INF.0000000000002590

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  Early-Onset Sepsis in Neonates - A Population-Based Study in South-West Norway From 1996 to 2018.

Authors:  Anlaug Vatne; Claus Klingenberg; Siren Rettedal; Knut Øymar
Journal:  Front Pediatr       Date:  2021-03-17       Impact factor: 3.418

Review 2.  Stratified Management for Bacterial Infections in Late Preterm and Term Neonates: Current Strategies and Future Opportunities Toward Precision Medicine.

Authors:  Fleur M Keij; Niek B Achten; Gerdien A Tramper-Stranders; Karel Allegaert; Annemarie M C van Rossum; Irwin K M Reiss; René F Kornelisse
Journal:  Front Pediatr       Date:  2021-04-01       Impact factor: 3.418

3.  Multicentre study found that adherence to national antibiotic recommendations for neonatal early-onset sepsis was low.

Authors:  Bo M van der Weijden; Niek B Achten; Jolita Bekhof; Esther E Evers; Mylène Berk; Arvid W A Kamps; Maarten Rijpert; Gavin W Ten Tusscher; Marlies A van Houten; Frans B Plötz
Journal:  Acta Paediatr       Date:  2020-08-10       Impact factor: 2.299

4.  Neonatal Early Onset Sepsis (EOS) Calculator plus Universal Serial Physical Examination (SPE): A Prospective Two-Step Implementation of a Neonatal EOS Prevention Protocol for Reduction of Sepsis Workup and Antibiotic Treatment.

Authors:  Francesco Cavigioli; Francesca Viaroli; Irene Daniele; Michela Paroli; Luigi Guglielmetti; Elena Esposito; Francesco Cerritelli; Gianvincenzo Zuccotti; Gianluca Lista
Journal:  Antibiotics (Basel)       Date:  2022-08-11

5.  Neonatal early-onset infections: Comparing the sensitivity of the neonatal early-onset sepsis calculator to the Dutch and the updated NICE guidelines in an observational cohort of culture-positive cases.

Authors:  Linde Snoek; Merel N van Kassel; Jurjen F Krommenhoek; Niek B Achten; Frans B Plötz; Nina M van Sorge; Matthijs C Brouwer; Diederik van de Beek; Merijn W Bijlsma
Journal:  EClinicalMedicine       Date:  2022-01-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.